2024-03-11
PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellulartherapies from the Chief Pharmaceutical Inspectorate in Poland.
2024-02-21
PolTREG appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to help it build partnerships across industry and deliver milestones
2024-02-07
Global institutional investors and investment funds hold over 25% of PolTREG’s shares.
2024-01-30
Prof. Piotr Trzonkowski co-authors peer-reviewed article showing scientific progress in T-regautoimmune therapy
2024-01-16
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
2024-01-15
The J.P. Morgan Healthcare Conference 2024 is already behind us!
2024-01-02
PolTREG at J.P. Morgan Healthcare Conference